GLP-1 medications may be linked to a lower risk of developing breast cancer in women, according to a large observational study [1].
This finding suggests that drugs primarily used for diabetes and weight loss may offer significant preventive benefits against one of the most common cancers in women. If validated by further clinical trials, these medications could potentially expand their therapeutic application beyond metabolic health.
The study monitored more than 111,000 women between the ages of 45 and 80 [1]. Researchers said that those using GLP-1 drugs experienced a notable reduction in breast cancer incidence compared to those not using the medications [1], [2].
Reports on the exact scale of the risk reduction vary slightly by source. One report indicates the risk was about 30% lower [1], while another source suggests the risk reduction was about 35% [2]. This range highlights a potential 30% to 35% decrease in the likelihood of developing the disease.
Researchers said that these drugs may have a preventive benefit against breast cancer [3]. While the primary function of GLP-1 receptor agonists is to regulate blood sugar and appetite, the data indicates a correlation with lower cancer rates in the studied cohort [1], [2].
The study's sample size—exceeding 111,000 participants—provides a substantial data set for observing these trends [1]. However, as an observational study, the results establish a link rather than a direct cause-and-effect relationship.
“GLP-1 medications may be linked to a lower risk of developing breast cancer in women”
The correlation between GLP-1 use and reduced breast cancer risk suggests that these medications may influence biological pathways related to tumor growth or inflammation. While these results are promising, they are based on observational data rather than controlled clinical trials, meaning further research is required to determine if the drugs directly prevent cancer or if other shared health factors among users contribute to the lower risk.
